Radionuclide Drug Conjugates (RDC) - Global Top Players Market Share and Ranking 2025- YH Research

日本语 | 中文

Home > Reports >Medical Care > Radionuclide Drug Conjugates (RDC) - Global Top Players Market Share and Ranking 2025

Radionuclide Drug Conjugates (RDC) - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-12-12
Report Id: 2862684
Industry: Medical Care
Report Page: 117
Chart: 115

PDF Download

Publication Date: 2025-12-12
Report Id: 2862684
Industry: Medical Care
Report Page: 117
Chart: 115

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Radionuclide Drug Conjugates (RDC) Definition
1.2 Global Radionuclide Drug Conjugates (RDC) Market Size and Forecast
1.3 China Radionuclide Drug Conjugates (RDC) Market Size and Forecast
1.4 Share of China Radionuclide Drug Conjugates (RDC) Market with Respect to the Global Market
1.5 Radionuclide Drug Conjugates (RDC) Market Size: China VS Global Growth Rate, 2020-2031
1.6 Radionuclide Drug Conjugates (RDC) Market Dynamics
1.6.1 Radionuclide Drug Conjugates (RDC) Market Drivers
1.6.2 Radionuclide Drug Conjugates (RDC) Market Restraints
1.6.3 Radionuclide Drug Conjugates (RDC) Industry Trends
1.6.4 Radionuclide Drug Conjugates (RDC) Industry Policy

2 Global Leading Players and Market Share
2.1 By Revenue of Radionuclide Drug Conjugates (RDC), Global Market Share by Company, 2020-2025
2.2 Global Radionuclide Drug Conjugates (RDC) Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Radionuclide Drug Conjugates (RDC) Concentration Ratio
2.4 Global Radionuclide Drug Conjugates (RDC) Mergers & Acquisitions, Expansion Plans
2.5 Global Radionuclide Drug Conjugates (RDC) Major Companies Product Type
2.6 Head Office and Area Served of Key Players

3 China Leading Players, Market Share and Ranking
3.1 By Revenue of Radionuclide Drug Conjugates (RDC), China Market Share by Company, 2020-2025
3.2 China Radionuclide Drug Conjugates (RDC) Radionuclide Drug Conjugates (RDC) Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis
4.1 Radionuclide Drug Conjugates (RDC) Industry Chain
4.2 Radionuclide Drug Conjugates (RDC) Upstream Analysis
4.2.1 Radionuclide Drug Conjugates (RDC) Core Raw Materials
4.2.2 Main Manufacturers of Radionuclide Drug Conjugates (RDC) Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Radionuclide Drug Conjugates (RDC) Production Mode
4.6 Radionuclide Drug Conjugates (RDC) Procurement Model
4.7 Radionuclide Drug Conjugates (RDC) Industry Sales Model and Sales Channels
4.7.1 Radionuclide Drug Conjugates (RDC) Sales Model
4.7.2 Radionuclide Drug Conjugates (RDC) Typical Distributors

5 Sights by Targeted Ligands
5.1 Radionuclide Drug Conjugates (RDC) Classification by Targeted Ligands
5.1.1 Small molecules
5.1.2 Peptides
5.1.3 Antibodies
5.2 by Targeted Ligands, Global Radionuclide Drug Conjugates (RDC) Consumption Value & CAGR, 2020 VS 2024 VS 2031
5.3 by Targeted Ligands, Global Radionuclide Drug Conjugates (RDC) Consumption Value, 2020-2031

6 Sights by Therapeutic Purposes
6.1 Radionuclide Drug Conjugates (RDC) Classification by Therapeutic Purposes
6.1.1 Therapeutic RDCs
6.1.2 Diagnostic RDCs
6.2 by Therapeutic Purposes, Global Radionuclide Drug Conjugates (RDC) Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Therapeutic Purposes, Global Radionuclide Drug Conjugates (RDC) Consumption Value, 2020-2031

7 Sights by Decay Types
7.1 Radionuclide Drug Conjugates (RDC) Classification by Decay Types
7.1.1 Alpha Nuclide RDCs
7.1.2 Beta Nuclide RDCs
7.2 by Decay Types, Global Radionuclide Drug Conjugates (RDC) Consumption Value & CAGR, 2020 VS 2024 VS 2031
7.3 by Decay Types, Global Radionuclide Drug Conjugates (RDC) Consumption Value, 2020-2031

8 Sights by Application
8.1 Radionuclide Drug Conjugates (RDC) Segment by Application
8.1.1 Prostate Cancer
8.1.2 Neuroendocrine Tumors
8.1.3 Liver Cancer
8.1.4 Kidney Cancer
8.1.5 Bone Metastases
8.1.6 Others
8.2 by Application, Global Radionuclide Drug Conjugates (RDC) Consumption Value & CAGR, 2020 VS 2024 VS 2031
8.3 by Application, Global Radionuclide Drug Conjugates (RDC) Consumption Value, 2020-2031

9 Sales Sights by Region
9.1 By Region, Global Radionuclide Drug Conjugates (RDC) Consumption Value, 2020 VS 2024 VS 2031
9.2 By Region, Global Radionuclide Drug Conjugates (RDC) Consumption Value, 2020-2031
9.3 North America
9.3.1 North America Radionuclide Drug Conjugates (RDC) Market Size & Forecasts, 2020-2031
9.3.2 By Country, North America Radionuclide Drug Conjugates (RDC) Market Size Market Share
9.4 Europe
9.4.1 Europe Radionuclide Drug Conjugates (RDC) Market Size & Forecasts, 2020-2031
9.4.2 By Country, Europe Radionuclide Drug Conjugates (RDC) Market Size Market Share
9.5 Asia Pacific
9.5.1 Asia Pacific Radionuclide Drug Conjugates (RDC) Market Size & Forecasts, 2020-2031
9.5.2 By Country/Region, Asia Pacific Radionuclide Drug Conjugates (RDC) Market Size Market Share
9.6 South America
9.6.1 South AmericaRadionuclide Drug Conjugates (RDC) Market Size & Forecasts, 2020-2031
9.6.2 By Country, South America Radionuclide Drug Conjugates (RDC) Market Size Market Share
9.7 Middle East & Africa

10 Sales Sights by Country Level
10.1 By Country, Global Radionuclide Drug Conjugates (RDC) Market Size & CAGR, 2020 VS 2024 VS 2031
10.2 By Country, Global Radionuclide Drug Conjugates (RDC) Consumption Value, 2020-2031
10.3 United States
10.3.1 United States Radionuclide Drug Conjugates (RDC) Market Size, 2020-2031
10.3.2 by Targeted Ligands, United States Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.3.3 by Application, United States Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.4 Europe
10.4.1 Europe Radionuclide Drug Conjugates (RDC) Market Size, 2020-2031
10.4.2 by Targeted Ligands, Europe Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.4.3 by Application, Europe Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.5 China
10.5.1 China Radionuclide Drug Conjugates (RDC) Market Size, 2020-2031
10.5.2 by Targeted Ligands, China Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.5.3 by Application, China Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.6 Japan
10.6.1 Japan Radionuclide Drug Conjugates (RDC) Market Size, 2020-2031
10.6.2 by Targeted Ligands, Japan Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.6.3 by Application, Japan Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.7 South Korea
10.7.1 South Korea Radionuclide Drug Conjugates (RDC) Market Size, 2020-2031
10.7.2 by Targeted Ligands, South Korea Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.7.3 by Application, South Korea Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.8 Southeast Asia
10.8.1 Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size, 2020-2031
10.8.2 by Targeted Ligands, Southeast Asia Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.8.3 by Application, Southeast Asia Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.9 India
10.9.1 India Radionuclide Drug Conjugates (RDC) Market Size, 2020-2031
10.9.2 by Targeted Ligands, India Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.9.3 by Application, India Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.10 Middle East & Africa
10.10.1 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size, 2020-2031
10.10.2 by Targeted Ligands, Middle East & Africa Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031
10.10.3 by Application, Middle East & Africa Radionuclide Drug Conjugates (RDC) Consumption Value Market Share, 2024 VS 2031

11 Company Profile
11.1 Novartis
11.1.1 Novartis Company Information, Head Office, Market Area, and Industry Position
11.1.2 Novartis Company Profile and Main Business
11.1.3 Novartis Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.1.4 Novartis Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.1.5 Novartis Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information, Head Office, Market Area, and Industry Position
11.2.2 Eli Lilly Company Profile and Main Business
11.2.3 Eli Lilly Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.2.4 Eli Lilly Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.2.5 Eli Lilly Recent Developments
11.3 Bayer
11.3.1 Bayer Company Information, Head Office, Market Area, and Industry Position
11.3.2 Bayer Company Profile and Main Business
11.3.3 Bayer Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.3.4 Bayer Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.3.5 Bayer Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Information, Head Office, Market Area, and Industry Position
11.4.2 Johnson & Johnson Company Profile and Main Business
11.4.3 Johnson & Johnson Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.4.4 Johnson & Johnson Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.4.5 Johnson & Johnson Recent Developments
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Information, Head Office, Market Area, and Industry Position
11.5.2 Bristol-Myers Squibb Company Profile and Main Business
11.5.3 Bristol-Myers Squibb Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.5.4 Bristol-Myers Squibb Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.5.5 Bristol-Myers Squibb Recent Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Company Information, Head Office, Market Area, and Industry Position
11.6.2 AstraZeneca Company Profile and Main Business
11.6.3 AstraZeneca Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.6.4 AstraZeneca Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.6.5 AstraZeneca Recent Developments
11.7 China Isotope & Radiation Corporation
11.7.1 China Isotope & Radiation Corporation Company Information, Head Office, Market Area, and Industry Position
11.7.2 China Isotope & Radiation Corporation Company Profile and Main Business
11.7.3 China Isotope & Radiation Corporation Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.7.4 China Isotope & Radiation Corporation Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.7.5 China Isotope & Radiation Corporation Recent Developments
11.8 Dongcheng Pharmaceutical
11.8.1 Dongcheng Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
11.8.2 Dongcheng Pharmaceutical Company Profile and Main Business
11.8.3 Dongcheng Pharmaceutical Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.8.4 Dongcheng Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.8.5 Dongcheng Pharmaceutical Recent Developments
11.9 Grand Pharmaceutical Group
11.9.1 Grand Pharmaceutical Group Company Information, Head Office, Market Area, and Industry Position
11.9.2 Grand Pharmaceutical Group Company Profile and Main Business
11.9.3 Grand Pharmaceutical Group Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.9.4 Grand Pharmaceutical Group Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.9.5 Grand Pharmaceutical Group Recent Developments
11.10 Hengrui Medicine
11.10.1 Hengrui Medicine Company Information, Head Office, Market Area, and Industry Position
11.10.2 Hengrui Medicine Company Profile and Main Business
11.10.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.10.4 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.10.5 Hengrui Medicine Recent Developments
11.11 Bivision
11.11.1 Bivision Company Information, Head Office, Market Area, and Industry Position
11.11.2 Bivision Company Profile and Main Business
11.11.3 Bivision Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.11.4 Bivision Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.11.5 Bivision Recent Developments
11.12 SmartNuclide
11.12.1 SmartNuclide Company Information, Head Office, Market Area, and Industry Position
11.12.2 SmartNuclide Company Profile and Main Business
11.12.3 SmartNuclide Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.12.4 SmartNuclide Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.12.5 SmartNuclide Recent Developments
11.13 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
11.13.1 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Information, Head Office, Market Area, and Industry Position
11.13.2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Company Profile and Main Business
11.13.3 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.13.4 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.13.5 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments
11.14 Xiantong Pharmaceutical
11.14.1 Xiantong Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
11.14.2 Xiantong Pharmaceutical Company Profile and Main Business
11.14.3 Xiantong Pharmaceutical Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.14.4 Xiantong Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.14.5 Xiantong Pharmaceutical Recent Developments
11.15 Full-Life Technologies
11.15.1 Full-Life Technologies Company Information, Head Office, Market Area, and Industry Position
11.15.2 Full-Life Technologies Company Profile and Main Business
11.15.3 Full-Life Technologies Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.15.4 Full-Life Technologies Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.15.5 Full-Life Technologies Recent Developments
11.16 Nuoyu Pharmaceutical
11.16.1 Nuoyu Pharmaceutical Company Information, Head Office, Market Area, and Industry Position
11.16.2 Nuoyu Pharmaceutical Company Profile and Main Business
11.16.3 Nuoyu Pharmaceutical Radionuclide Drug Conjugates (RDC) Models, Specifications, and Application
11.16.4 Nuoyu Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue and Gross Margin, 2020-2025
11.16.5 Nuoyu Pharmaceutical Recent Developments

12 Conclusion

13 Appendix
13.1 Research Methodology
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Market Estimation Model
13.4 Disclaimer

According to YH Research, the global market for Radionuclide Drug Conjugates (RDC) should grow from US$ 9532 million in 2024 to US$ 14645 million by 2031, with a CAGR of 6.4% for the period of 2025-2031.

Radionuclide-conjugated drugs (RCDs) are complex molecules for precise targeted therapy and diagnosis, composed of three core elements: a targeting ligand, a linker, and a radionuclide. Their mechanism of action is similar to a "biologically guided miniature nuclear bomb": the targeting ligand specifically recognizes and binds to biomarkers highly expressed on the surface of diseased cells such as tumors; the linker ensures the stability of the entire molecule; and the radionuclide acts as the "warhead," accumulating at the target site and releasing ionizing radiation energy such as alpha and beta particles to destroy tumor cells from within, or releasing gamma/positron rays for highly sensitive molecular imaging diagnosis. This design achieves precise, "visualized" targeting of diseases and is a prime example of the deep integration of nuclear medicine and targeted drug technology.

Radionuclide Drug Conjugates (RDC)

According to YH Research, the global market for Radionuclide Drug Conjugates (RDC) should grow from US$ 9532 million in 2024 to US$ 14645 million by 2031, with a CAGR of 6.4% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The field of RCDs is experiencing explosive growth, with a broad and clear development prospect. Future trends will focus on: first, target diversification and drug iteration, with RDCs targeting new targets such as CLDN18.2 and FAP rapidly entering clinical trials, and the development of better ligands. Second, the advancement of treatment paradigms: the highly promising alpha radionuclide therapy holds the potential to conquer more complex and drug-resistant solid tumors, becoming a core next-generation treatment method. Third, the deep integration of diagnosis and treatment: patient stratification and personalized dosage regimens based on precise imaging will become standard procedures, greatly improving treatment efficiency and safety. Fourth, technological platform innovation: more stable connectivity technologies, prodrug strategies, and combination therapies will continuously expand its application boundaries. Overall, RDC is evolving from a "powerful tool" for a few specific cancer types into an indispensable precision diagnosis and treatment platform in oncology and even some non-oncology diseases.

This report studies and analyses global Radionuclide Drug Conjugates (RDC) status and future trends, to help determine the Radionuclide Drug Conjugates (RDC) market size of the total market opportunity by Targeted Ligands, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Radionuclide Drug Conjugates (RDC), and provides market size (US$ million) and Year-over-Year growth, considering 2023 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Radionuclide Drug Conjugates (RDC) market size, history data 2019-2024, and forecast data 2025 -2030, (US$ million)
(2) Global Radionuclide Drug Conjugates (RDC) by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(3) China Radionuclide Drug Conjugates (RDC) by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(4) Global Radionuclide Drug Conjugates (RDC) key consuming regions, consumption value and demand structure
(5) Radionuclide Drug Conjugates (RDC) industry chains, upstream, midstream and downstream
Market segment by players, this report covers
    Novartis
    Eli Lilly
    Bayer
    Johnson & Johnson
    Bristol-Myers Squibb
    AstraZeneca
    China Isotope & Radiation Corporation
    Dongcheng Pharmaceutical
    Grand Pharmaceutical Group
    Hengrui Medicine
    Bivision
    SmartNuclide
    Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
    Xiantong Pharmaceutical
    Full-Life Technologies
    Nuoyu Pharmaceutical

Market segment by Targeted Ligands, covers
    Small molecules
    Peptides
    Antibodies

Market segment by Application, can be divided into
    Prostate Cancer
    Neuroendocrine Tumors
    Liver Cancer
    Kidney Cancer
    Bone Metastases
    Others

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Radionuclide Drug Conjugates (RDC) product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Radionuclide Drug Conjugates (RDC) market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 3: China Radionuclide Drug Conjugates (RDC) market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 4: Radionuclide Drug Conjugates (RDC) industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Targeted Ligands, consumption value, percent & CAGR, 2019-2030
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2019-2030
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2019-2030
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2019-2030
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions